Clinical Trial Update: Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating a gene-modified immune cell therapy after a conditioning regimen for metastatic melanoma and other metastatic solid tumors, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Head and Neck Squamous Cell Carcinoma
• Lung Adenocarcinoma
• Melanoma
• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor
• Pheochromocytoma
• Uveal Melanoma

Drugs mentioned

• Investigational gene-modified immune cell therapy (NCT04119024)

Snippet

Sponsor: Anusha Kalbasi | Conditions: Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Status: RECRUITING